Desjardins Global Asset Management Inc. Vertex Pharmaceuticals Inc Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 6,036 shares of VRTX stock, worth $3.03 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
6,036
Previous 6,430
6.13%
Holding current value
$3.03 Million
Previous $2.24 Million
9.84%
% of portfolio
0.27%
Previous 0.25%
Shares
9 transactions
Others Institutions Holding VRTX
# of Institutions
1,716Shares Held
225MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$13.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.89 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.29 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $129B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...